- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about NUMIF
Recent news which mentions NUMIF
Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions
November 15, 2024
From Benzinga
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
September 12, 2024
From Benzinga
Psychedelics Co. Numinus Narrows Loss In Q3, Reports QoQ Decrease In Revenue, Gross Profit
July 12, 2024
From Benzinga
Psychedelics-Focused Numinus Plans To Leverage This AI Technology Via New Strategic Acquisition
June 22, 2024
From Benzinga
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
April 15, 2024
From Benzinga
From Benzinga
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
March 25, 2024
From Benzinga
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
March 16, 2024
From Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
From Benzinga
Why Is MindMed (MNMD) Stock Up 8% Today?
February 12, 2024
From InvestorPlace
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
From Benzinga
Numinus Wellness Continues Tight Expense Management With Strategic Reviews Underway
January 18, 2024
From Benzinga
From Benzinga
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
December 05, 2023
From Benzinga
Numinus Reports Q4 & Full Year Fiscal 2023 Results, Including Greatly Reduced Cash Burn Rate
November 30, 2023
Tickers
NUMIF
From Benzinga
Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News
September 15, 2023
Tickers
NUMIF
From Benzinga
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
September 12, 2023
From Benzinga
MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
June 20, 2023
From Benzinga
Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study
June 16, 2023
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
From Benzinga
Numinus Wellness CEO Payton Nyquvest On Q2 2023 Financial Results And Numinus Network
April 19, 2023
Tickers
NUMIF
From Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
April 17, 2023
From Benzinga
EXCLUSIVE: Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth'
April 13, 2023
From Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
April 13, 2023
From Benzinga
Psychedelic Stock Gainers And Losers From April 12, 2023
April 12, 2023
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.